Vyvanse Generics Approved by FDA
September 1, 2023The U.S. Food and Drug Administration (FDA) has approved several generic forms of Vyvanse (lisdexamfetamine dimesylate), the stimulant medication used to treat ADHD in patients six years or older and moderate-to-severe binge-eating disorder (BED) in adults.1Fourteen companies may now manufacture and sell generic versions of Vyvanse capsules and chewable tablets, according to the FDA.
Takeda Pharmaceuticals’ U.S. patent for Vyvanse expired on August 24. Generic versions of drugs, which provide the same clinical benefits and risks as their brand-name counterparts, are often available at significant cost savings for patients.
The FDA stipulates that generic ADHD medications contain exactly the active ingredients as their name-brand counterparts; however, compounds in generic drugs are allowed to include different binding chemicals, fillers, and colors.Vyvanse was the most popular prescription stimulant according to a July 2023 ADDitude survey of 11,000 readers on ADHD treatment.
Read more on additudemag.com
